Michel Boutin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/616944/publications.pdf

Version: 2024-02-01

46 papers	1,067 citations	430874 18 h-index	414414 32 g-index
46 all docs	46 docs citations	46 times ranked	1112 citing authors

#	Article	IF	Citations
1	Lysosphingolipid urine screening test using mass spectrometry for theÂearly detection of lysosomal storage disorders. Bioanalysis, 2022, 14, 289-306.	1.5	1
2	Quantitation of a plasma biomarker profile for the early detection of Gaucher disease type 1 patients. Bioanalysis, 2022, 14, 223-240.	1.5	0
3	Metabolomic Study Using Time-of-Flight Mass Spectrometry Reveals Novel Urinary Biomarkers for Gaucher Disease Type 1. Journal of Proteome Research, 2022, 21, 1321-1329.	3.7	2
4	Methylmalonic acid analysis using urine filter paper samples to screen for metabolic vitamin B₁₂ deficiency in older adults. Bioanalysis, 2022, 14, 615-626.	1.5	1
5	Vitamin B-12 Intake from Dairy but Not Meat Is Associated with Decreased Risk of Low Vitamin B-12 Status and Deficiency in Older Adults from Quebec, Canada. Journal of Nutrition, 2022, 152, 2483-2492.	2.9	8
6	Quantitation of a Urinary Profile of Biomarkers in Gaucher Disease Type 1 Patients Using Tandem Mass Spectrometry. Diagnostics, 2022, 12, 1414.	2.6	3
7	Lentivirus-mediated gene therapy for Fabry disease. Nature Communications, 2021, 12, 1178.	12.8	58
8	Neonatal Urine Screening Program in the Province of Quebec: Technological Upgrade from Thin Layer Chromatography to Tandem Mass Spectrometry. International Journal of Neonatal Screening, 2021, 7, 18.	3.2	4
9	Globotriaosylsphingosine (lyso-Gb3) and analogues in plasma and urine of patients with Fabry disease and correlations with long-term treatment and genotypes in a nationwide female Danish cohort. Journal of Medical Genetics, 2021, 58, 692-700.	3.2	13
10	The clinical utility of total concentration of urinary globotriaosylsphingosine plus its analogues in the diagnosis of Fabry disease. Clinica Chimica Acta, 2020, 500, 120-127.	1.1	13
11	Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles. International Journal of Molecular Sciences, 2020, 21, 6114.	4.1	3
12	Assessing the role of glycosphingolipids in the phenotype severity of Fabry disease mouse model. Journal of Lipid Research, 2020, 61, 1410-1423.	4.2	7
13	Identification of a Reliable Biomarker Profile for the Diagnosis of Gaucher Disease Type 1 Patients Using a Mass Spectrometry-Based Metabolomic Approach. International Journal of Molecular Sciences, 2020, 21, 7869.	4.1	11
14	Effects of Orally Delivered Alpha-Galactosidase A on Gastrointestinal Symptoms in Patients With Fabry Disease. Gastroenterology, 2020, 159, 1602-1604.	1.3	11
15	Therapeutic challenges in two adolescent male patients with Fabry disease and high antibody titres. Molecular Genetics and Metabolism Reports, 2020, 24, 100618.	1.1	2
16	Mass Spectrometry Evaluation of Biomarkers in the Vitreous Fluid in Gaucher Disease Type 3 with Disease Progression Despite Long-Term Treatment. Diagnostics, 2020, 10, 69.	2.6	0
17	Mass spectrometry analysis of urinary methylmalonic acid to screen for metabolic vitamin B deficiency in older adults. Bioanalysis, 2020, 12, 693-705.	1.5	8
18	Distribution of heparan sulfate and dermatan sulfate in mucopolysaccharidosis type II mouse tissues pre- and post-enzyme-replacement therapy determined by UPLCâ€“MS/MS. Bioanalysis, 2019, 11, 727-740.	1.5	6

#	Article	IF	Citations
19	Tandem mass spectrometry analysis of urinary podocalyxin and podocin in the investigation of podocyturia in women with preeclampsia and Fabry disease patients. Clinica Chimica Acta, 2019, 495, 67-75.	1.1	17
20	Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy. Journal of Medical Genetics, 2019, 56, 548-556.	3.2	43
21	Neonatal Mass Urine Screening Approach for Early Detection of Mucopolysaccharidoses by UPLC-MS/MS. Diagnostics, 2019, 9, 195.	2.6	8
22	Globotriaosylsphingosine (Lysoâ€Gb₃) as a biomarker for cardiac variant (N215S) Fabry disease. Journal of Inherited Metabolic Disease, 2018, 41, 239-247.	3.6	25
23	Analysis of globotriaosylceramide (Gb 3) isoforms/analogs in unfractionated leukocytes, B lymphocytes and monocytes from Fabry patients using ultra-high performance liquid chromatography/tandem mass spectrometry. Analytica Chimica Acta, 2018, 1015, 35-49.	5.4	9
24	The lysosomal enzyme alpha-Galactosidase A is deficient in Parkinson's disease brain in association with the pathologic accumulation of alpha-synuclein. Neurobiology of Disease, 2018, 110, 68-81.	4.4	38
25	Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation. Clinica Chimica Acta, 2017, 466, 185-193.	1.1	44
26	Highâ€Risk Screening for Fabry Disease: Analysis by Tandem Mass Spectrometry of Globotriaosylceramide (Gb 3) in Urine Collected on Filter Paper. Current Protocols in Human Genetics, 2017, 93, 17.26.1-17.26.12.	3.5	10
27	Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34 + Cells for Correction of Fabry Disease. Molecular Therapy - Methods and Clinical Development, 2017, 5, 241-258.	4.1	36
28	Separation and Analysis of Lactosylceramide, Galabiosylceramide, and Globotriaosylceramide by LC-MS/MS in Urine of Fabry Disease Patients. Analytical Chemistry, 2017, 89, 13382-13390.	6.5	31
29	Glycosphingolipid storage in Fabry mice extends beyond globotriaosylceramide and is affected by ABCB1 depletion. Future Science OA, 2016, 2, FSO147.	1.9	6
30	Evaluation of urinary keratan sulfate disaccharides in MPS IVA patients using UPLCâ€“MS/MS. Bioanalysis, 2016, 8, 179-191.	1.5	17
31	Tandem Mass Spectrometry Quantitation of Lysoâ€Gb 3 and Six Related Analogs in Plasma for Fabry Disease Patients. Current Protocols in Human Genetics, 2016, 90, 17.23.1-17.23.9.	3.5	14
32	Maternal inhaled fluticasone propionate intake during pregnancy is detected in neonatal cord blood. Bioanalysis, 2016, 8, 1441-1450.	1.5	2
33	Fabry Disease Biomarkers: Analysis of Urinary Lysoâ€Gb 3 and Seven Related Analogs Using Tandem Mass Spectrometry. Current Protocols in Human Genetics, 2016, 90, 17.22.1-17.22.12.	3.5	8
34	Relative distribution of Gb₃ isoforms/analogs in NOD/SCID/Fabry mice tissues determined by tandem mass spectrometry. Bioanalysis, 2016, 8, 1793-1807.	1.5	14
35	Highâ€Risk Screening of Fabry Disease: Analysis of Fifteen Urinary Methylated and Nonâ€Methylated Gb 3 Isoforms Using Tandem Mass Spectrometry. Current Protocols in Human Genetics, 2016, 91, 17.24.1-17.24.11.	3.5	1
36	Diagnosis of late-onset Pompe disease and other muscle disorders by next-generation sequencing. Orphanet Journal of Rare Diseases, 2016, 11, 8.	2.7	42

#	Article	IF	Citations
37	Tandem Mass Spectrometry Multiplex Analysis of Glucosylceramide and Galactosylceramide Isoforms in Brain Tissues at Different Stages of Parkinson Disease. Analytical Chemistry, 2016, 88, 1856-1863.	6.5	68
38	Tandem mass spectrometry multiplex analysis of methylated and non-methylated urinary Gb3 isoforms in Fabry disease patients. Clinica Chimica Acta, 2016, 452, 191-198.	1.1	23
39	Metabolomic Discovery of Novel Urinary Galabiosylceramideâ€‰Analogs as Fabry Disease Biomarkers. Journal of the American Society for Mass Spectrometry, 2015, 26, 499-510.	2.8	42
40	Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma. Clinica Chimica Acta, 2015, 447, 96-104.	1.1	22
41	Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry. Clinica Chimica Acta, 2015, 438, 195-204.	1.1	62
42	Multiplex Tandem Mass Spectrometry Analysis of Novel Plasma Lyso-Gb₃-Related Analogues in Fabry Disease. Analytical Chemistry, 2014, 86, 3476-3483.	6.5	71
43	A Metabolomic Study To Identify New Globotriaosylceramide-Related Biomarkers in the Plasma of Fabry Disease Patients. Analytical Chemistry, 2013, 85, 9039-9048.	6.5	56
44	Multiplex Analysis of Novel Urinary Lyso-Gb₃-Related Biomarkers for Fabry Disease by Tandem Mass Spectrometry. Analytical Chemistry, 2013, 85, 1743-1752.	6.5	72
45	LCâ€“MS/MS analysis of plasma lyso-Gb3 in Fabry disease. Clinica Chimica Acta, 2012, 414, 273-280.	1.1	53
46	Urinary Globotriaosylsphingosine-Related Biomarkers for Fabry Disease Targeted by Metabolomics. Analytical Chemistry, 2012, 84, 2745-2753.	6.5	82